Litcius/Paper detail

Non-peptide, once-per-day oral orforglipron to compete with established peptide-based, injectable GLP-1 receptor agonists

Michael A. Nauck, Michael Horowitz

2023The Lancet13 citationsDOI

Topics & Concepts

ExenatideDulaglutideSemaglutideLiraglutideGlucagon-like peptide 1 receptorMedicineType 2 diabetesAgonistInternal medicinePharmacologyAdverse effectEndocrinologyReceptorDiabetes mellitusDiabetes Treatment and ManagementPharmacology and Obesity TreatmentMetabolism, Diabetes, and Cancer
Non-peptide, once-per-day oral orforglipron to compete with established peptide-based, injectable GLP-1 receptor agonists | Litcius